Eisai scores FDA priority review for bigger Lenvima use in kidney cancer

Eisai's thyroid cancer drug Lenvima stepped into the FDA's fast lane for a new use. The agency granted Lenvima priority review as a treatment for advanced kidney cancer, which could be a much more lucrative indication. More than 61,000 patients will be diagnosed with kidney cancer this year, Eisai says; the approval would cover Lenvima in combination with Novartis' ($NVS) Afinitor in patients who've failed on previous VEGF therapy. Release

Read more on